Project cooperationUpdated on 9 April 2026
ASP210
About
ASP210 is a therapeutic oligonucleotide leveraging the ESiNAR-X platform to target BCR-ABL1 mRNA in patients with chronic myeloid leukemia who are resistant or refractory to TKI therapy.
Status: Finished pre-clinical validation
We are seeking investments and partnerships to support the execution of clinical trials.
Similar opportunities
Expertise
Humanized multi-organoid models for translational drug discovery
Agne Vaitkeviciene
Business Development Director at abc biopply
Solothurn, Switzerland